AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Ehlers-Danlos Syndrome

Recent research efforts aimed at curing Ehlers-Danlos Syndrome.

Last updated

Ehlers-Danlos Syndrome

Overview

Ehlers-Danlos syndromes (EDS) are a genetically diverse group of inherited connective-tissue conditions. Connective tissue provides structural support to skin, joints, blood vessels, and internal organs; when it is affected, people may experience joint hypermobility and instability, chronic pain, stretchy or fragile skin, abnormal scarring, easy bruising, and—in some subtypes—serious eye, heart, blood-vessel, bowel, or pregnancy complications. The 2017 classification recognizes 13 EDS types; 12 have known single-gene causes, while hypermobile EDS (hEDS), the most commonly diagnosed type, still has no confirmed diagnostic gene or laboratory test. Genetic diagnosis of EDS Ehlers-Danlos syndromes overview

Prognosis varies substantially by subtype. Many people with hEDS or classical EDS have a normal life expectancy but can have considerable disability from pain, recurrent injuries, fatigue, and related symptoms. Vascular EDS (vEDS), usually caused by pathogenic variants in COL3A1, carries risks of arterial, intestinal, and uterine rupture and requires specialized surveillance and emergency planning. There is no approved curative therapy for any EDS subtype; current care is individualized and focuses on physical and occupational therapy, pain and symptom management, injury prevention, skin and wound care, genetic counseling, and subtype-specific cardiovascular monitoring and risk reduction. Vascular EDS GeneReviews Ehlers-Danlos syndromes overview

Scope of Recent Research (2020–present)

Research activity has increased meaningfully since 2020, especially in vEDS drug prevention studies and in efforts to identify the biological basis of hEDS. The dominant questions are whether vascular complications can be prevented by repurposed medicines, whether faulty collagen folding or cell-stress pathways can be corrected, and whether hEDS can be subdivided into genetically and biologically defined conditions that enable targeted treatment. The field is not yet close to a whole-body cure: no gene therapy, gene-editing treatment, RNA therapy, or cell therapy has entered clinical trials for EDS, and the absence of a confirmed cause for most hEDS remains a central barrier. Genetic diagnosis of EDS HEDGE study update

Major Breakthroughs and Emerging Therapies

The clearest recent clinical advance concerns vEDS rather than a cure. In the randomized Phase 3 ARCADE trial, 57 adults with vEDS receiving background celiprolol were assigned to irbesartan or placebo for two years. The composite outcome of arterial events or new/worsening arterial lesions occurred in 8 of 29 participants receiving irbesartan and 15 of 28 receiving placebo, corresponding to a hazard ratio of 0.42. Irbesartan caused episodes of hypotension in some participants, and the evidence applies specifically to its use as an add-on to celiprolol; importantly, this approach reduces vascular risk but does not repair the underlying COL3A1 variant. ARCADE irbesartan trial

Mechanism-based small-molecule research is now addressing the abnormal collagen itself. A 2025 study of fibroblasts from people with vEDS found that two disease-causing glycine substitutions in type III collagen caused misfolded collagen secretion, retention of collagen inside the endoplasmic reticulum, cell stress, reduced cell growth, and extracellular-matrix defects. The chemical chaperone 4-phenylbutyrate (4-PBA)—a medicine already approved for another indication—improved collagen stability, reduced cell stress and cell death, and improved matrix defects in those patient-derived cells. This is an important proof of concept, but it is not evidence that 4-PBA is effective or safe for people with vEDS, and its effects differed by mutation and treatment conditions. 4-PBA rescues vEDS cell defects

A second preclinical strategy targets harmful signaling downstream of defective collagen. In a 2020 vEDS mouse-model study, inhibition of the PKC/MEK/ERK signaling pathway, including treatment with the MEK inhibitor cobimetinib, improved survival in one Col3a1 model. A separate 2022 mouse study found that losartan markedly improved survival in a different Col3a1 model, while beta-blockers and several other blood-pressure medicines did not show the same benefit. These contrasting results show both the promise and the difficulty of drug repurposing: the biological response can depend on the precise collagen variant, animal model, tissue, and outcome measured. Targetable signaling in vEDS mice Comparative therapies in a vEDS mouse model

For hEDS, the most consequential emerging “therapy” work remains disease-definition research rather than a direct treatment. The international HEDGE study has analyzed 1,021 whole-genome sequences from people meeting 2017 hEDS criteria, while a 2025 genome-wide association study meta-analysis of approximately 1,700 hEDS cases and 5,000 controls reported evidence that common genetic variants may contribute to hEDS risk. These findings support a complex, likely multi-gene model rather than a single universal hEDS gene; they are useful for future diagnostics and drug-target discovery but do not yet establish a treatment target suitable for gene replacement or editing. HEDGE study update hEDS genome-wide association meta-analysis

Clinical Trials and Experimental Approaches

ARCADE (NCT02597361), sponsored by Assistance Publique–Hôpitaux de Paris, was a completed multicenter Phase 3 randomized, double-blind, placebo-controlled trial of irbesartan added to celiprolol in molecularly confirmed vEDS. Its published results provide the strongest recent controlled clinical evidence for reducing vascular events and imaging-detected lesion progression in vEDS, although the sample was necessarily small because vEDS is rare. ARCADE trial record ARCADE irbesartan trial

The ongoing DiSCOVER trial (NCT05432466), sponsored by Acer Therapeutics, is a decentralized Phase 3, randomized, double-blind, placebo-controlled trial of celiprolol in approximately 150 participants aged 15 to 64 years with pathogenic or likely pathogenic COL3A1 variants causing vEDS. As of its latest posted record, it was recruiting, with estimated primary completion in March 2029; no efficacy results have been posted. DiSCOVER celiprolol trial

For hEDS, registered interventional studies remain largely symptom-focused rather than curative. Examples include a Baylor College of Medicine pilot study of intravenous oxytocin for chronic pain in adult women with hEDS and a Tulane University Phase 3-design study of ultrasound-guided dextrose prolotherapy for low-back and sacroiliac pain; neither is designed to correct the disease’s root biology, and neither had published therapeutic outcomes at the time of this report. Oxytocin protocol for hEDS Dextrose prolotherapy trial

Methodologies and Scientific Approaches

Researchers are combining patient-derived cells, engineered animal models, tissue imaging, and multi-omics approaches. In vEDS, primary skin fibroblasts are used to measure collagen folding, secretion, extracellular-matrix organization, and endoplasmic-reticulum stress, while genetically engineered Col3a1 mice permit survival, arterial rupture, blood-pressure, biomechanics, and drug-response studies that cannot be conducted experimentally in people. These platforms are valuable for identifying mutation-specific mechanisms, but they cannot fully reproduce a lifelong multisystem disease in humans. 4-PBA rescues vEDS cell defects Comparative therapies in a vEDS mouse model

In hEDS, major efforts use whole-genome sequencing, genome-wide association studies, clinical registries, proteomics, skin biopsies, and candidate biomarkers to separate biologically distinct patient groups. Funded projects now include patient-specific three-dimensional skin-tissue models, skin extracellular-matrix biomarker studies, and genomic/proteomic programs intended to reveal drug targets. 2024 EDS Society funded research NIH-supported hEDS mechanisms project

Leading Institutions and Funding

Important vEDS clinical research has been led by French teams at Assistance Publique–Hôpitaux de Paris, Université Paris Cité, INSERM, and collaborating national rare-vascular-disease centers through the ARCADE trial. Basic vEDS collagen-folding research has involved the University of Glasgow, Ghent University Hospital, and the University of Münster. In the United States, Acer Therapeutics sponsors the ongoing DiSCOVER celiprolol trial. ARCADE irbesartan trial 4-PBA rescues vEDS cell defects DiSCOVER celiprolol trial

The Ehlers-Danlos Society has become a substantial disease-specific funder. Its 2024 portfolio included $2.5 million for a biobank, $2 million for hEDS digestive-comorbidity research, $900,000 for pathophysiological and therapeutic-marker grants, $300,000 for skin-biomarker work, and $2.3 million through its Research Inner Circle. Named awards included $1,299,333 for patient-specific three-dimensional EDS skin models at the University of Colorado Anschutz Medical Campus and $1,049,469 for a Stanford multi-omics hEDS/HSD project. NIH also supported a Medical University of South Carolina fellowship on genetic and molecular mechanisms of hEDS with a reported total award amount of $170,483. 2024 EDS Society funded research NIH-supported hEDS mechanisms project

Strengths, Limitations, and Challenges

The major strength of the recent field is a shift from purely supportive care toward biologically informed intervention. ARCADE demonstrated that a relatively accessible existing drug can reduce clinically meaningful vEDS vascular outcomes, while cell and mouse studies have identified collagen misfolding, cellular stress, and abnormal signaling as potentially druggable processes. Large international genomic studies and patient registries are also beginning to provide the sample sizes needed to study a heterogeneous condition such as hEDS. ARCADE irbesartan trial 4-PBA rescues vEDS cell defects HEDGE study update

The limitations are fundamental. EDS is not one disease but a set of disorders with different genes, inheritance patterns, tissues affected, and mechanisms; a therapy for a COL3A1-related vEDS subgroup may not help classical, hypermobile, or recessive EDS types. hEDS has no validated molecular diagnosis or proven causal gene, making participant selection, biomarker development, and target-based trials difficult. Even for vEDS, the ARCADE trial was small, tested irbesartan on a background of celiprolol, and used a composite endpoint that included imaging-detected lesion changes as well as clinical events. Whole-body correction of inherited connective tissue would require safe delivery to many tissues and durable benefit without disrupting normal collagen biology, which remains far beyond current clinical technology. Genetic diagnosis of EDS ARCADE irbesartan trial

Outlook and Future Directions

As of October 14, 2026, a cure for EDS is not imminent, but the trajectory is more encouraging for risk modification in vEDS and for biological stratification in hEDS. The next milestones to watch are publication and replication of hEDS genomic and biomarker findings, translation of 4-PBA or related collagen-folding approaches from patient cells into animal safety and efficacy studies, results from the DiSCOVER celiprolol trial, and confirmation that ARCADE’s irbesartan benefit is durable and applicable across COL3A1 variant groups. A true cure will likely require subtype-specific approaches—potentially combining genetic diagnosis, mutation-aware molecular treatments, and safe body-wide delivery—rather than a single treatment for all EDS. DiSCOVER celiprolol trial 4-PBA rescues vEDS cell defects

References

Don't see your disease? Request a report